Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Anebulo Pharmaceuticals Inc (ANEB)

Anebulo Pharmaceuticals Inc (ANEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,728
  • Shares Outstanding, K 41,085
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,200 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta -1.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings $-0.09 on 02/14/25
  • Next Earnings Date 05/21/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +1,665,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9400 +4.26%
on 04/16/25
1.3000 -24.62%
on 05/07/25
+0.0048 (+0.49%)
since 04/11/25
3-Month
0.9001 +8.88%
on 04/09/25
2.1900 -55.25%
on 03/19/25
-0.4600 (-31.94%)
since 02/12/25
52-Week
0.8001 +22.48%
on 12/20/24
3.1002 -68.39%
on 05/13/24
-2.0300 (-67.44%)
since 05/10/24

Most Recent Stories

More News
Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...

ANEB : 0.9800 (-5.77%)
Ligand Reports First Quarter 2023 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management...

TVTX : 21.54 (+7.59%)
VKTX : 28.30 (+2.72%)
LGND : 106.38 (+1.82%)
ANEB : 0.9800 (-5.77%)
NVS : 108.95 (+0.23%)
NOVN : 0.0941 (-24.84%)
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel...

ANEB : 0.9800 (-5.77%)
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company”...

ANEB : 0.9800 (-5.77%)
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (“ACI”) and substance addiction...

ANEB : 0.9800 (-5.77%)
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company”...

ANEB : 0.9800 (-5.77%)
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder...

ANEB : 0.9800 (-5.77%)
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction...

ANEB : 0.9800 (-5.77%)
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction...

ANEB : 0.9800 (-5.77%)
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder...

ANEB : 0.9800 (-5.77%)

Business Summary

Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 1.1267
2nd Resistance Point 1.0933
1st Resistance Point 1.0367
Last Price 0.9800
1st Support Level 0.9467
2nd Support Level 0.9133
3rd Support Level 0.8567

See More

52-Week High 3.1002
Fibonacci 61.8% 2.2216
Fibonacci 50% 1.9502
Fibonacci 38.2% 1.6787
Last Price 0.9800
52-Week Low 0.8001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar